Approach to desensitization in aspirin-exacerbated respiratory disease
Annals of Allergy, Asthma & Immunology
January 2014 Volume 112, Issue 1, Pages 13-17 MOC CME Review
Participants will be able to demonstrate increased knowledge of the clinical treatment of allergy/asthma/immunology and how new information can be applied to their own practices.
Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Planning Committee Members:
Andrew A. White, MD (Author)
Michael S. Tankersley, MD (CME Series Editor)
Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief)
Physicians involved in providing patient care in the field of allergy/asthma/immunology
At the conclusion of this activity, participants should be able to:
- Discuss the common clinical findings in aspirin exacerbated respiratory disease
- Describe a systematic approach to evaluating and treating patients with suspected aspirin exacerbated respiratory disease
David R. Scott, MD; and Andrew A. White, MD
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Attendance